Journal
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Volume 83, Issue 5, Pages 1239-1253Publisher
MOSBY-ELSEVIER
DOI: 10.1016/j.jaad.2020.03.131
Keywords
basal cell carcinoma; checkpoint inhibitor; CTLA-4 inhibitor; cutaneous lymphomas; cutaneous malignancies; cutaneous squamous cell carcinoma; immunotherapy; Kaposi sarcoma; melanoma; Merkel cell carcinoma; PD-1 inhibitor; PD-L1 inhibitor; skin cancer
Categories
Funding
- National Cancer Institute Cancer Center support grant [P30 CA008748]
- National Institute of Arthritis and Musculoskeletal and Skin Diseases [U01AR07751]
- National Cancer Institute [5P01CA225517]
Ask authors/readers for more resources
As the incidence of cutaneous malignancies continues to rise and their treatment with immunotherapy expands, dermatologists and their patients are more likely to encounter immune checkpoint inhibitors. While the blockade of immune checkpoint target proteins (cytotoxic T-lymphocyte-associated protein-4, programmed cell death-1, and programmed cell death ligand-1) generates an antitumor response in a substantial fraction of patients, there is a critical need for reliable predictive biomarkers and approaches to address refractory disease. The first article of this Continuing Medical Education series reviews the indications, efficacy, safety profile, and evidence supporting checkpoint inhibition as therapeutics for metastatic melanoma, cutaneous squamous cell carcinoma, and Merkel cell carcinoma. Pivotal studies resulting in the approval of ipilimumab, pembrolizumab, nivolumab, cemiplimab, and avelumab by regulatory agencies for various cutaneous malignancies, as well as ongoing clinical research trials, are discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available